Coulie Bernard reported PLRX

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001746473-26-000017

Machine-readable

Structured copy

Timestamps

Event (reported)

Jan 22, 2026

Published

Jan 26, 2026

Ingested by INSIDER

Nov 5, 04:20 UTC

Last re-read

Nov 5, 04:20 UTC

Extracted facts

Filer

Coulie Bernard

Role

Director, President and CEO

Transaction

Grant or awardAs filed: “A”

Asset

PLIANT THERAPEUTICS, INC. — Stock Option (Right to Buy)

Ticker

PLRX

Shares

1.23M

Price per share

$0

Execution date (reported)

Jan 22, 2026

Owned after transaction

1.23M shares

Days from execution to publication

4

What this establishes

Coulie Bernard filed this Form 4 reporting a grant or award of PLRX on Jan 22, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director, President and CEO

Coulie Bernardcik:0001808895

Issuer

PLIANT THERAPEUTICS, INC.cik:0001746473

Revision history · 0

No field has changed since this record was first ingested.